Actinium Pharmaceuticals (ATNM)
(Real Time Quote from BATS)
$6.82 USD
-0.24 (-3.40%)
Updated Apr 25, 2024 01:24 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATNM 6.82 -0.24(-3.40%)
Will ATNM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
Other News for ATNM
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals' Iomab-B improves survival in refractory AML
Actinium Pharmaceuticals: A Strong Buy on Regulatory Advances and Strategic Positioning
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Actinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising Pipeline